Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for MRK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 717.00M
December 31, 2025 1.205B
September 30, 2025 1.309B
June 30, 2025 1.333B
March 31, 2025 1.145B
December 31, 2024 477.00M
September 30, 2024 439.00M
June 30, 2024 178.00M
March 31, 2024 35.00M
December 31, 2023 387.00M
September 30, 2023 459.00M
June 30, 2023 256.00M
March 31, 2023 119.00M
December 31, 2022 -265.00M
September 30, 2022 -10.00M
June 30, 2022 -97.00M
March 31, 2022 -12.00M
December 31, 2021 -116.00M
September 30, 2021 566.00M
June 30, 2021 197.00M
March 31, 2021 -9.00M
December 31, 2020 -21.00M
September 30, 2020 -28.00M
June 30, 2020 -14.00M
March 31, 2020 1.255B
Date Value
December 31, 2019 1.033B
September 30, 2019 1.365B
June 30, 2019 1.104B
March 31, 2019 917.00M
December 31, 2018 5.803B
September 30, 2018 834.00M
June 30, 2018 1.527B
March 31, 2018 336.00M
December 31, 2017 1.684B
September 30, 2017 86.00M
June 30, 2017 1.039B
March 31, 2017 706.00M
December 31, 2016 867.00M
September 30, 2016 436.00M
June 30, 2016 481.00M
March 31, 2016 711.00M
December 31, 2015 1.13B
September 30, 2015 1.224B
June 30, 2015 574.00M
March 31, 2015 773.00M
December 31, 2014 1.441B
September 30, 2014 2.423B
June 30, 2014 2.043B
March 31, 2014 236.00M
December 31, 2013 -205.00M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Johnson & Johnson -138.00M
Eli Lilly & Co. 2.356B
Pfizer Inc. 0.00
Bristol Myers Squibb Co. 0.00
AstraZeneca PLC 600.99M